EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin

Jun Zhou, Qiang-Sheng Wang

Frontiers in Pharmacology · 18.06.2026 · 17

DOI: 10.3389/fphar.2026.1809310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.06.2026. Verfasst von Jun Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytochrome P450 family two subfamily C member 19 (CYP2C19) loss-of-function (LOF) variants may influence clopidogrel response after percutaneous coronary intervention (PCI), but their prognostic relevance within combined clinical and procedural risk assessment remains incompletely defined. This study aimed to evaluate the association between CYP2C19 functional phenotype and major adverse cardiac and cerebrovascular events (MACCE) in coronary artery disease (CAD) patients receiving clopidogrel-based dual antiplatelet therapy (DAPT) after PCI.

Method

This retrospective observational study included 280 consecutive CAD patients who underwent PCI with stent implantation and received aspirin plus clopidogrel. The primary endpoint was time to first MACCE. Multivariable Cox proportional hazards regression was the primary analysis, with logistic regression as a secondary supportive analysis. Kaplan-Meier analysis, subgroup interaction analyses, and sensitivity analyses were performed.

Results

During a median follow-up of 32.0 months, 52 patients experienced MACCE (18.6%). In the primary Cox model, older age, diabetes mellitus, lower estimated glomerular filtration rate, lower left ventricular ejection fraction, greater total stent length, post-procedural Thrombolysis In Myocardial Infarction (MI) flow <3, and CYP2C19 LOF phenotype were associated with time to first MACCE. CYP2C19 LOF remained significant after adjustment (adjusted hazard ratio 1.74, 95% confidence interval 1.10–2.75; P = 0.018). Kaplan-Meier analysis showed lower MACCE-free survival in LOF carriers than in non-LOF patients (log-rank P = 0.007). Interaction analyses suggested stronger LOF-associated risk patterns in acute coronary syndrome and complex PCI subgroups.

Conclusion

In clopidogrel-treated CAD patients after PCI, CYP2C19 LOF phenotype was associated with MACCE in a clinical–procedural risk framework. These findings support further prospective validation of integrated genotype-informed post-PCI risk stratification.

Schlagwörter

Stichwörter der Autor:innen

aspirinclopidogrelcoronary artery diseasedual antiplatelet therapymajor adverse cardiovascular eventspercutaneous coronary intervention

Autor:innen und Institutionen

  • Department of Cardiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of General Practice, The Headquarters of Beijing Nuclear Industry Hospital, Beijing, China.

Zitieren

APA

Zhou, J., & Wang, Q. S. (2026). Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1809310

Vancouver

Zhou J, Wang QS. Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1809310

BibTeX
@article{Zhou2026,
  author = {Zhou, Jun and Wang, Qiang-Sheng},
  title = {Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1809310}
}
Kostenlos starten →